Reaction
Gastrointestinal Fistula reporting signals
As of the last recalculation, Gastrointestinal Fistula appears in 867 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 42.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 23 | 42.1 | 42.1 |
| Adalimumab | 407 | 25.1 | 25.2 |
| Vedolizumab | 39 | 11.3 | 11.3 |
| Bevacizumab | 55 | 11.3 | 11.3 |
| Regorafenib | 5 | 10.4 | 10.4 |
| Lenvatinib | 12 | 8.9 | 8.9 |
| Cetuximab | 11 | 8.5 | 8.5 |